Caristar Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 9.48%
- Profit Growth -79.08%
- Ebitda 16.08%
- Net Worth 10.19%
- Total Assets -10.84%
About Caristar Laboratories
Caristar Laboratories Private Limited (CLPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 31 October 2011 and has a history of 13 years and four months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Puerto Rico Pharmaceutical Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ari Mukamal, Ramachandran Subrahmaniam, and Daniel Mukamal serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233MH2011PTC223522
- Company No.
223522
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Oct 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Caristar Laboratories?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Daniel Mukamal  | Director | 01-Jan-2012 | Current |
| Ari Mukamal | Director | 23-Aug-2013 | Current |
Ramachandran Subrahmaniam  | Director | 02-Jun-2021 | Current |
Financial Performance of Caristar Laboratories.
Caristar Laboratories Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.48% increase. The company also saw a substantial fall in profitability, with a 79.08% decrease in profit. The company's net worth Soared by an impressive increase of 10.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Caristar Laboratories?
In 2023, Caristar Laboratories had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Madison Ortho LlpDaniel Mukamal is a mutual person
Ignexto Biotex Private LimitedRamachandran Subrahmaniam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Caristar Laboratories?
Caristar Laboratories has a workforce of 24 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Caristar Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Caristar Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
